Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Reata Pharmaceuticals, Inc.
ClinicalTrials.gov Identifier:
NCT00535314
First received: September 24, 2007
Last updated: October 27, 2014
Last verified: October 2014
  Purpose

The primary purpose of the study is to determine the proportion of patients without progression at 6-months in patients with unresectable Stage III or Stage IV melanoma who are taking RTA 402.


Condition Intervention Phase
Malignant Melanoma
Drug: RTA 402 Dose1
Drug: RTA 402 Dose2
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Phase II, Randomized, Open Label Trial of 2 Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

Resource links provided by NLM:


Further study details as provided by Reata Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • To determine the proportion of patients without progression at 6 months in patients with unresectable Stage III or Stage IV melanoma treated with RTA 402.

Secondary Outcome Measures:
  • To determine the overall response rate and duration of responses

Enrollment: 0
Arms Assigned Interventions
Experimental: RTA 402 Dose1
Dose1 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
Drug: RTA 402 Dose1
Experimental: RTA 402 Dose2
Dose2 of RTA 402 to be administered orally once daily for 28 consecutive days, for up to 18 months.
Drug: RTA 402 Dose2

Detailed Description:

This is a phase II, open label, randomized study in patients with unresectable Stage III or Stage IV malignant melanoma. Patients will be randomly assigned to two different doses of RTA 402 administered orally once daily for 28 consecutive days, for up to 18 months.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Greater than or equal to 18 years of age
  • Confirmed diagnosis of malignant (unresectable Stage III or Stage IV) melanoma
  • Measurable disease, defined as at least 1 lesion which measures more than or equal to 20 mm by conventional techniques, or more than or equal to 10 mm by spiral CT scan, or cutaneous lesion of greater than or equal to 10 mm by caliper.
  • May have received no more than 1 prior chemotherapy for metastatic disease.
  • May have received prior vaccine therapy in the adjuvant setting.
  • May have received cytokine therapy in the adjuvant setting and/or 1 prior cytokine therapy for metastatic disease.
  • ECOG performance of 0-1
  • Must have adequate liver and renal function documented by laboratory test results.
  • Must have adequate bone marrow function documented by lab results.
  • Must have completed any prior chemotherapy, immunotherapy, radiation, biological, or other investigational cancer therapy at least 4 weeks prior to starting this study, and have recovered from all acute side effects. Patients receiving mitomycin C or nitrosoureas must be 6 weeks from the last administration of chemotherapy.
  • Man or woman must agree to practice effective contraception during the study and for at least 2 months after the last dose of RTA 402.
  • Must have life expectancy of more than 3 months.
  • Must be willing and able to sign the informed consent form.
  • Must be willing and able to take and document oral doses of RTA 402.

Exclusion Criteria:

  • May have received no more than 1 prior chemotherapy.
  • May have received no more than 1 prior cytokine therapy for metastatic disease.
  • Diagnosis of ocular melanoma.
  • Inability to swallow tablets or capsules
  • Symptomatic malabsorptive disorder (eg, Crohn's Disease), or removal of either the terminal ileus or more than 2/3 of the small intestine.
  • Active brain metastases or primary central nervous system malignancies; patients with a previously treated brain metastasis may be included provided that there is no requirement for steroids and no evidence for progression for greater than or equal to 8 weeks after treatment.
  • Active second malignancy.
  • Weight loss greater than or equal to 10% over the 6 weeks prior to dosing
  • Pregnant or breast feeding
  • Clinically significant illnesses which could compromise participation in the study, including: uncontrolled diabetes; active or uncontrolled infection; acute or chronic liver disease; confirmed diagnosis of HIV infection; uncontrolled hypertension, symptomatic congestive heart failure, unstable angina pectoris, myocardial infarction within the last 6 months, or uncontrolled cardiac arrhythmia.
  • Psychiatric illness that would limit compliance with study requirements.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

No Contacts or Locations Provided
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00535314     History of Changes
Other Study ID Numbers: RTA 402-C-0704
Study First Received: September 24, 2007
Last Updated: October 27, 2014
Health Authority: United States: Food and Drug Administration

Keywords provided by Reata Pharmaceuticals, Inc.:
Melanoma

Additional relevant MeSH terms:
Melanoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas

ClinicalTrials.gov processed this record on November 24, 2014